Home » Accelr8 2012 Revenues Narrow Sharply

Accelr8 2012 Revenues Narrow Sharply

Oct 29, 2012
|
a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 Technology on Friday reported a sharp drop in revenues for its Fiscal Year 2012.

In a document filed with the US Securities and Exchange Commission, the company said that revenues dropped to $235,910 for its Fiscal Year 2012 ended July 31, 2012, compared to $1.1 million in Fiscal Year 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Articles

Jan 13, 2015

JP Morgan Healthcare Conference, Day Two: Thermo Fisher Scientific, Affymetrix, Danaher, Hologic, Genmark, Accelerate Diagnostics

Mar 17, 2014

DiagnoCure Q1 Revenues Fall 12 Percent on Weak Sales of Hologic-marketed Prostate Cancer Assay

Mar 10, 2014

Accelerate Dx 2013 Revenues Down 8 Percent

Nov 04, 2014

MDxHealth's Q3 Revenues Rise 78 Percent

Oct 08, 2014

Genetic Technologies Reports 'Consistent' Q1 BREVAGen Volume, Launches Second Generation Dx

Premium
Apr 16, 2014

Life Tech 2013 Revenues Inch up 2 Percent

The Scan

This Week in Nature

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Bits of Evidence

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Return on Microbiome Research

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus to Leave NCI

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

What's Popular?

In Clinical & Translational

  1. Contextual Genomics to Beta Test Affordable Cancer Panel for Personalizing Cancer Therapy in Canada

    Premium

  2. Study Links Subset of Rare Genomic Disorders to Low-level Somatic Mosaicism in Parents

  3. EGAPP Issues Cancer Genetic Test Recommendations

  4. Sequenom to Launch VisibiliT for Average-Risk Pregnancies Outside US, Expand MaterniT21 Plus

    Premium

  5. Natera Preps Move into Cancer Dx Market as it Continues Building NIPT Capabilities

Sponsorships

Privacy Policy.  Copyright © 2015 Genomeweb LLC.  All Rights Reserved.